Actinium Pharmaceuticals, Inc. (ATNM) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple validated cancer targets, including CD45, CD33, CD38, CD47, HER2, and HER3 for targeted conditioning prior to cell and gene therapies, such as bone marrow transplant and cancer therapeutics as single agents or in combination with other therapeutic modalities. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company was incorporated in 2000 and is based in New York, New York.
Actinium Pharmaceuticals, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
NYSE · Pharmaceutical Preparations
4 readings, 1 filed under bull and 3 under bear. Every figure is ours; the model chose the side.
the bull case· 1
47
managers reporting a position in thirteen f filings
13fJun 30 '26the bear case· 3
9
managers whose positions together make up four fifths of reported value
13fJun 30 '2613 of 22
of the largest reporting managers cut their stake in the latest quarter
13fJun 30 '26−8.06%
change in shares held by the ten largest reporting managers over the latest quarter
13fJun 30 '26The model filed each reading under bull or bear and wrote its caption; a caption carrying a digit is replaced by our own phrase, so every figure on this zone is ours. Built Sep 16 '26 against the Nov 10 '26 report; rebuilt when that date rolls. Not a forecast, not advice.
Prev close 1.26 · gapped above the open, then crossed back over prior close. High/low 1.31 at 9:45 am ET, 1.25 at 6:00 pm ET.
ATNM (Actinium Pharmaceuticals, Inc.) has 0 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
tall tick = annual report · 1 on record
Actinium Pharmaceuticals, Inc. has no measured co-movers clearing our correlation floor, so only its SEC classification is shown.
SIC 2834, Pharmaceutical Preparations, from each company's own filings. Largest first.
47 managers report a position worth $5.2M between them, and 9 of them hold 80% of it.